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Structural grey matter covariance networks provide an individual quantiﬁcation of morphological patterns in the brain. The network integrity is disrupted in sporadic Alzheimer’s disease, and network properties show associations with the level of amyloid
pathology and cognitive decline. Therefore, these network properties might be disease progression markers. However, it remains
unclear when and how grey matter network integrity changes with disease progression. We investigated these questions in autosomal dominant Alzheimer’s disease mutation carriers, whose conserved age at dementia onset allows individual staging based
upon their estimated years to symptom onset. From the Dominantly Inherited Alzheimer Network observational cohort, we
selected T1-weighted MRI scans from 269 mutation carriers and 170 non-carriers (mean age 38 6 15 years, mean estimated years
to symptom onset 9 6 11), of whom 237 had longitudinal scans with a mean follow-up of 3.0 years. Single-subject grey matter
networks were extracted, and we calculated for each individual the network properties which describe the network topology,
including the size, clustering, path length and small worldness. We determined at which time point mutation carriers and non-carriers diverged for global and regional grey matter network metrics, both cross-sectionally and for rate of change over time. Based
on cross-sectional data, the earliest difference was observed in normalized path length, which was decreased for mutation carriers
in the precuneus area at 13 years and on a global level 12 years before estimated symptom onset. Based on longitudinal data, we
found the earliest difference between groups on a global level 6 years before symptom onset, with a greater rate of decline of network size for mutation carriers. We further compared grey matter network small worldness with established biomarkers for
Alzheimer disease (i.e. amyloid accumulation, cortical thickness, brain metabolism and cognitive function). We found that greater
amyloid accumulation at baseline was associated with faster decline of small worldness over time, and decline in grey matter network measures over time was accompanied by decline in brain metabolism, cortical thinning and cognitive decline. In summary,
network measures decline in autosomal dominant Alzheimer’s disease, which is alike sporadic Alzheimer’s disease, and the properties show decline over time prior to estimated symptom onset. These data suggest that single-subject networks properties obtained
from structural MRI scans form an additional non-invasive tool for understanding the substrate of cognitive decline and measuring
progression from preclinical to severe clinical stages of Alzheimer’s disease.
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age at onset of dementia can be estimated, from the age
at onset in family members or carriers of the same specific mutation type. The estimated years to symptom onset
(EYO) can serve as a proxy for disease duration
(Bateman et al., 2012; Ryman et al., 2014). Using this
paradigm, previous work demonstrated that Ab aggregation starts more than two decades before dementia onset
(Gordon et al., 2018; McDade et al., 2018; Oxtoby
et al., 2018). Closer to symptom onset, individuals show
accelerated hypometabolism and cortical thinning, which
is followed by cognitive decline (Benzinger et al., 2013;
Kinnunen et al., 2018; Wang et al., 2019). When during
these processes, grey matter networks start to decline
remains unknown.
Here, we investigated for the first time single-subject grey
matter networks over the course of ADAD. We assessed
when, and how, the network properties change as a function of EYO, both cross-sectionally and longitudinally, on
a global and regional level. To understand the relationship
between grey matter network property changes and disease
progression, we also investigated how the network smallworld coefficient alters with established Alzheimer’s disease
markers of Ab accumulation, brain metabolism, cortical
thickness and cognitive function.

Materials and methods
DIAN study design and participants
In the worldwide Dominantly Inherent Alzheimer
Network (DIAN) longitudinal cohort study, families with
individuals carrying a PSEN1, PSEN2 or APP mutation
undergo genetic testing and repeated clinical, cognitive,
fluid and brain imaging assessments. The non-carrier
family members act as an inherent control group.
Participants generally have study visits every 3 years at
earlier disease stages and these assessments become yearly
when either symptoms are present, or they are within 3
years of their EYO. DIAN protocols had supervisory approval from the ethical review board of Washington
University in St. Louis, and all participants gave informed
consent. For this study, we selected data from all participants who had undergone at least one MRI scan that
passed quality control in the 12th data freeze. Families
with the Dutch or Flemish APP mutation were excluded
because these mutations result in a different phenotype,
with predominantly cerebral amyloid angiopathy.

Estimated years to symptom onset
We calculated the EYO for mutation carriers and noncarriers identically: The EYO was defined as the mutation-specific mean age at onset subtracted by the individuals’ visit age (Ryman et al., 2014). In case of an
unknown mutation-specific age at onset, the parental age
at disease onset, reported by the participant, was used
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In order to advance clinical trials to slow or halt
Alzheimer’s disease, the most frequent cause of dementia
(Scheltens et al., 2016), it is important both to understand the evolution of pathophysiological changes occurring and to develop disease progression markers (Aisen
et al., 2017). Current biomarkers reliably detect
Alzheimer’s disease pathology (Jack et al., 2018), however, predicting and monitoring disease progression remain difficult. Brain network properties are linked to
cognitive function (Bassett and Bullmore, 2009; Chhatwal
et al., 2018; Franzmeier et al., 2018), therefore studying
network integrity may offer new insights into disease progression in Alzheimer’s disease.
One way to measure of brain networks is by determining the similarity of grey matter morphological measures
between brain regions across individuals, i.e. grey matter
covariance networks (He et al., 2008; Li et al., 2012;
Tijms et al., 2012) (Fig. 1). This approach is based on
the notion that brain regions involved in distinct cognitive functions tend to develop in a similar way, possibly
due to shared neurotrophic factors (Zielinski et al., 2010;
Alexander-Bloch et al., 2013a, b). Common developmental trajectories and functional co-activation result in similar grey matter tissue properties, as measured on
structural MRI (Draganski et al., 2004; Mechelli et al.,
2005; Seeley et al., 2009). These covariance patterns are
related to normal cognition (Seidlitz et al., 2018; Doucet
et al., 2019) and reveal in healthy individuals an optimal,
‘small-world’, organization by graph theory description
(He et al., 2007; Humphries and Gurney, 2008). In sporadic Alzheimer’s disease dementia, grey matter networks
are disrupted, the properties show a less optimal, random
organization of the network (Yao et al., 2010; Tijms
et al., 2013a; Kim et al., 2016). In pre-dementia stages,
such loss of network integrity predicts clinical progression
and cognitive decline (Dicks et al., 2018; Tijms et al.,
2018). The presence of amyloid b (Ab) pathology in cognitively normal individuals has also been associated with
grey matter network alterations (Tijms et al., 2016; Ten
Kate et al., 2018; Voevodskaya et al., 2018). Together,
these observations suggest that these network properties
change over the course of Alzheimer’s disease, from early
stages, and that individual grey matter network extractions could possibly be used to monitor disease progression. However, as previous findings were based on onetime network extractions, it remains unclear whether, and
when, these networks change within individuals as they
progress in their disease.
A complication when studying sporadic Alzheimer’s disease is the difficulty of placing pre-symptomatic individuals on their disease timeline (Villemagne et al., 2013;
Donohue et al., 2014; Young et al., 2014; Roe et al.,
2018; Vermunt et al., 2019). This issue is less problematic for carriers of a genetic mutation that causes autosomal dominant Alzheimer’s disease (ADAD), because the
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then random clustering. This is optimal, because of fast exchange of
information between remote clusters, and specialized information
processing within clusters.

Clinical evaluation and cognition
Disease severity was measured using the Clinical
Dementia Rating scale (CDR) (Morris, 1993), administered to the participant and study partner by blinded
raters. Participants were classified as being unimpaired
(global CDR score ¼ 0) or symptomatic (global CDR 0.5,
1, 2 and 3). In addition, cognitive function was summarized using a cognitive composite developed in the DIAN
project (Bateman et al., 2017), consisting of the average
of equally weighted Z-scores of the Logical Memory
delayed recall total score from the Wechsler Memory
Scale-Revised, DIAN Word List Test delayed free recall
score, Digit Symbol Coding total score from the Wechsler
Adult Intelligence Scale-Revised Digit Symbol Substitution
Test, and the total score from the Mini-Mental State
Examination.
Figure 1 Details on grey matter network metrics. (With
permission from Verfaillie et al. 2018, Human Brain
Mapping.) (A) Grey matter network extraction from the
individual brain segmentation (described in text). (B) The sum of
the number of nodes, i.e. the number of cubes, is the size of the
network. The degree is the average number of connections per
node. The connectivity density is the percentage of the number of
connections in the network compared to the maximum number of
connections possible. The clustering coefficient of a node describes
the proportion of connections between neighbours for every node.
For example, in case a node connects to 3 other nodes, there are 3
possible connections between those 3 adjacent nodes. If only 1
connection is present between 2 of the 3 other nodes, the
clustering of the primary node is 1 out of 3, 0.33. Global clustering
is determined by taking averaging clustering values across all nodes.
Path length is the mean of the shortest paths for a node to reach
every other node in the network. The global path length is the
average path length across all nodes. (C) Normalized clustering and
normalized path length describe how on a global level a network
organization differs from a randomly organized network. The
networks are randomized by rewiring the connections randomly in
each network, while keeping intact the total number of nodes and
degrees (Maslov and Sneppen, 2002). The network’s observed
clustering and path length are divided by the clustering and path
length values, respectively, of averaged random networks to obtain
the normalized values. Lastly, the small-world coefficient is the
normalized clustering divided by the normalized path length. The
network has the ‘small-world property’ if this ratio is higher than 1,
indicating a path length close to the random networks, yet a greater

MRI acquisition and pre-processing
MRI T1-weighted scans (1.11.11.2 mm3 voxels, repetition time ¼ 2300 ms, echo time ¼ 2.95 ms, flip angle 9 )
were acquired according to Alzheimer’s Disease
Neuroimaging Initiative (ADNI) protocols (Jack et al.,
2010). We segmented T1 images into grey and white matter and CSF, using the Statistical Parametric Mapping
software version 12 (SPM12; Wellcome Trust Centre for
Neuroimaging, UCL Institute of Neurology, London, UK).
All segmentations were checked visually, after which 51
scans were removed due to failed segmentations or severe
motion artefacts. Native space grey matter segmentations
were resampled into 2  2  2 mm3 voxels. This voxelwise data were used as input for connectivity analyses.

Single-subject grey matter networks
and metrics
Grey matter networks were computed according to a previously published, automated pipeline (Tijms et al., 2012)
that includes two steps figurated in Fig. 1A: (i) grey matter network extraction (https://github.com/bettytijms/Single_
Subject_Grey_Matter_Networks, accessed December 2019;
implemented in Matlab2016b (MathWorks, Natick, MA))
and (ii) graph theory-based metric calculation (Rubinov
and Sporns, 2010; Tijms et al., 2012). To extract single-
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instead. For example, if the mean age at symptom onset
for a specific mutation is 50 years, then a 35-year-old individual would have an EYO of 15. For the carriers of
the ADAD mutation, this indicates that the individual is
expected to show clinical symptoms of Alzheimer’s disease 15 years later.

Grey matter network decline in Alzheimer

Other DIAN imaging data
We examined regional data for Ab using PET imaging
with 11 C-Pittsburgh Compound B (Ab PET), glucose metabolism with 18F-Fluorodeoxyglucose PET (FDG-PET),
and cortical thickness and volumes from structural MRI.
Details on data processing have previously been described
(Gordon et al., 2018). The Freesurfer ROIs were used to
process the amyloid and FDG-PET data. PET data are
processed using a cerebellar grey reference region and
partial volume corrected using a geometric transfer matrix approach (Su et al., 2013; Su et al., 2015). In this
study, we utilized the MRI precuneus cortical thickness,
the precuneus Ab PET and to match a previously defined
meta-ROI, the average of the left and right isthmus cingulate and inferior parietal region in FDG-PET for cross-
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modal comparison with grey matter network properties
(Landau et al., 2011).

Statistical analyses
As part of sample characterization, we compared four
groups (non-carriers; asymptomatic mutation carriers
with an EYO before 15 years; asymptomatic mutation
carriers with EYO between 15 and 0 years; and symptomatic mutation carriers) on cross-sectional grey matter
network small-world values, and the other network measures with the Kruskal–Wallis test, and post hoc Wilcoxon
test with Holm P-value adjustment. We extracted individual slopes with linear mixed models in R for those individuals with repeated measures. Using the same statistical
tests, we compared those extracted slopes between the
groups. In addition, we compared individuals with different mutation types (PSEN1/PSEN2/APP) on the baseline
network property values.
For the main analyses, we compared mutation carriers
and non-carriers to determine (i) the EYO at which grey
matter network metrics showed cross-sectional differences
between groups and (ii) the EYO at which the groups
had a different rate of change over time by fitting linear
mixed effects models. Specifically, we used Bayesian inference methods (Gordon et al., 2018; Mishra et al., 2018)
to determine the EYO point that 99% credible intervals
of the difference distribution did not overlap 0. In these
methods, the model parameters were estimated as previously described, applying a Hamiltonian Markov chain
Monte Carlo sampling of the posterior distribution, with
10 000 iterations in eight chains, 5000 warm-up, thinning retaining 1 out of every 10 iterations and cauchy
prior in the STAN package for R. We checked the model

convergence statistic Gelman–Rubin diagnostic, the Rstatistic (rhat), which compares the between and withinchain estimates for each of the model parameters. These
should be at least close to 1.0 and were for all models
close to 1.00. (Gelman et al., 2015; Carpenter et al.,
2017). From the posterior distribution, we calculated the
range 99% credible intervals around the estimates, i.e.
0.005–0.995 range. We also calculated the difference
curve between the mutation carriers and non-carriers by
EYO with 99% credible intervals. We refer to the ‘divergence point’ as the point where the 99% credible interval
of this difference curve between carriers and non-carriers
did not contain 0 (i.e. no difference). The credible interval is the Bayesian equivalent of the frequentist confidence interval. The main difference is that the Bayesian
directly estimates the credible interval from an actual
computed population (i.e. posterior) distributions, rather
than hypothesized as in the frequentists approach.
Therefore, an advantage of the Bayesian approach is that
the credible interval can be interpreted in a probabilistic
way. To allow for non-linear effects, without assuming a
particular shape, we applied a restricted cubic spline with
knots at the 0.10, 0.50 and 0.90 of the EYO
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subject grey matter networks, we parcellated each individual’s native space grey matter segmentation into 6  6 
6 mm3 cubes, containing 27 voxels. These non-overlapping cubes serve as the ‘nodes’ in the network.
Connections between each pair of cubes across an individual’s scan were established by calculating the
Pearson’s correlation coefficient between the corresponding voxels. This approach takes into account both the
grey matter probability (i.e. from the tissue segmentation)
as well as the spatial information present in 27 voxels
within each cube. All correlations were stored in a matrix, and the presence or absence of connections between
nodes was dichotomized according to an individualized
threshold that ensured a maximum of 5% spurious connections for each individual (Tijms et al., 2012).
For each individual’s binarized grey matter network,
we calculated graph theory metrics describing the global
network properties: size, degree, connectivity density,
clustering coefficient, path length, normalized clustering,
normalized path length and small-world coefficient (see
Fig. 1B and C for explanation of these metrics). We also
calculated regional network properties. In order to aid
comparability with other studies previously performed in
DIAN, regional network metrics were calculated within
each region of the Desikan-Killiany atlas (Desikan et al.,
2006). The regional masks were obtained by first parcellating each individual’s T1 image into 34 anatomical
regions of interest (ROIs) from the Desikan atlas using
Freesurfer 5.3 (Fischl, 2012) (http://surfer.nmr.mgh.har
vard.edu, accessed December 2019). The Freesurfer output was then aligned to the native space T1 using FSL
(https://fsl.fmrib.ox.ac.uk/fsl, accessed December 2019),
and this transform was used to register the parcellation
into native space. The network values of the degree, clustering coefficient and path length were subsequently averaged within a region. Graph theory metrics were
calculated using scripts from the brain connectivity toolbox (https://sites.google.com/site/bctnet/, accessed December
2019), modified for large-sized networks.
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Data availability
The data from the DIAN study can be requested online
at https://dian.wustl.edu/, accessed December 2019.

Results
In total, 439 participants from the DIAN study, with a mean
6 SD age of 38 6 11 years and a mean 6 SD EYO of
9 6 11, had MRI scans of sufficient quality to be included
in the present analyses. The group consisted of 269 (61%)
ADAD mutation carriers and 170 (39%) non-carrier family
members (Table 1). Of this sample, 237 (54%) participants
had longitudinal MRI scans, with a mean of 2.5 scans per
participant and a maximum of 6 acquired over a mean 6
SD 3.0 6 1.5 years of follow-up (clinical and PET data in
Supplementary Table 1). There were groups differences between asymptomatic mutation carriers with EYO < 15 years,
asymptomatic mutation carriers 15<EYO < 0 years, symptomatic mutation carriers and non-carriers on cross-sectional
network values and extracted slopes (Supplementary Figs 3
and 4). For most network measures, we found that the mutation carriers who are far away from expected onset (EYO
>15 years) and the non-carriers had slightly higher network
property value than mutation carriers who were closer to
expected symptom onset, and it further decreased in the symptomatic stage. Rate of decline showed a similar pattern between these groups. Figure 2 illustrates these comparisons for
the small-world coefficient. Comparing PSEN1/PSEN2/APP
mutation carriers at baseline on all network metrics, the
network size and average degree were slightly lower in
PSEN1 carriers, while the other metrics were similar
(Supplementary Fig. 5).

Cross-sectional divergences between
mutation carriers and non-carriers
The mutation carriers diverged from non-carriers on all grey
matter network metrics, except for network size and raw
path length (Fig. 3, Supplementary Table 2). Lower network
metric values for mutation carriers relative to non-carriers
were observed earliest in normalized path length at EYO
12, followed by lower normalized clustering at EYO 8.7,
small-world coefficient at EYO 8.4, clustering coefficient at
EYO 7.5, connectivity density at EYO 5.6 and degree at
EYO 0. When additionally adjusting for degree or connectivity density, the estimates for network metrics yielded similar
results (Supplementary Table 2). Using the same methods,
but now implemented on a regional level, the earliest divergence between mutation carriers relative to non-carriers was
found for path length in the precuneus at EYO 13.1, for
clustering in the superior temporal gyrus at EYO 10 and for
network degree in the banks of the superior temporal gyrus
at EYO 7 (Fig. 4, Supplementary Table 3).
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distribution, also described previously (Gordon et al.,
2018) that included a linear term (EYOlinear) and a
cubic term (EYOcubic). Cross-sectional models contained
fixed terms for EYO, mutation status, their interaction
and a random effect for family cluster. Longitudinal models were used to study the rate of change of network
properties, and individuals with one data point were also
included. Those models included fixed terms for baseline
EYO (two terms: EYOlinear and EYOcubic), time after
baseline, mutation status and, all two- and three-way
interactions (see formulas in Supplementary material, p.
6). Additionally, all models included random intercept
terms for subject and family cluster and a random slope
for subject. The covariates whole-brain grey matter volume and sex were included as fixed terms. Equivalent to
previous work, when size, degree or connectivity density
were found to be associated with mutation status in any
of the models, were included as additional covariates for
sensitivity analysis as these variables also influence more
complex network metrics (Tijms et al., 2013a). Regional
models were adjusted for sex, regional degree and regional grey matter volume.
We examined relationships between grey matter network small-world coefficient and established Alzheimer’s
disease markers within mutation carriers. Previous research suggested grey matter networks may be disrupted
in response to Ab accumulation, precipitating cognitive
decline (Ten Kate et al., 2018). For this reason, our models included either precuneus PET Ab as a predictor and
grey matter network metrics as outcomes or grey matter
network metrics as a predictor and cortical thickness
(precuneus), brain metabolism (meta-ROI), or cognition
(DIAN cognitive composite) as the respective outcomes.
These predictors and outcomes were Z-scored to the
whole group. We fitted three sets of linear mixed effects
models that were all adjusted for baseline grey matter
volume, age, and sex, and with random intercept for
family cluster, in lme4 package in R (Bates et al., 2014)
(see detailed formulas in Supplementary material, p. 6). If
models failed to converge, the term for family cluster was
removed. Models were divided into three sections. The
first was baseline comparisons. The second set was longitudinal comparisons in participants with at least two
data points to avoid convergence issues and included
additional random effects for subject intercept and slope
of the predictor. The final set of models was used to
evaluate whether baseline data could predict change over
time in the outcome. These models had fixed effects for
baseline predictor, time from baseline, and its interaction,
and a random subject intercept and slope of time from
baseline. We focused on the grey matter network smallworld coefficient, as this metric is indirectly derived from
all other network metrics, and can thus be considered a
summary statistic (Fig. 1). We also show exploratory
graphs for the other network measures for completeness
and repeated as a sensitivity analysis the cross-modal
models for the mutation carriers only.

L. Vermunt et al.
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Divergences of rates of change
between mutation carriers
compared to non-carriers

Association of grey matter
networks with other neuroimaging
and cognition
Established markers of Alzheimer’s disease showed significant relationships with the small-world coefficient used as
a global network summary statistic. We examined crossmodal relationships between baseline markers; over
repeated measures; and whether baseline values could
predict further decline in the other marker. We found
that higher Ab deposition load on PET was cross-sectionally related to a lower small-world coefficient (b 6 SE ¼
0.22 6 0.05, P ¼ 3  106, Fig. 5). In a longitudinal design, faster amyloid accumulation over time related to
concurrent small-world coefficient decline (b 6 SE ¼
0.33 6 0.06, P ¼ 1  107). Thirdly, a higher amyloid
load at baseline predicted steeper decline of the small-

world coefficient over time (b 6 SE ¼ 0.07 6 0.01,
P ¼ 4  108).
Grey matter network small-world coefficient and the
markers of Alzheimer’s disease progression showed significant relationships, both cross-sectionally and longitudinally (Fig. 6). Specifically, a lower small-world
coefficient was cross-sectionally related to lower FDGPET metabolism in the meta-ROI (b 6 SE ¼ 0.44 6 0.08,
P ¼ 2  107), as well as lower precuneus cortical thickness (b 6 SE ¼ 0.50 6 0.06, P ¼ 2  1015). For cognition, a lower small-world coefficient was cross-sectionally
related to lower scores on the DIAN cognitive composite
(b 6 SE ¼ 0.28 6 0.08, P ¼ 3  104). In a longitudinal
design, decline of the small-world coefficient over time
related to concurrent decreases of FDG-PET metabolism
(b 6 SE ¼ 0.54 6 0.06, P ¼ 5  1014) and faster precuneus cortical thinning (b 6 SE ¼ 0.55 6 0.06, P ¼ 1 
1017). A declining small-world coefficient over time was
related to concurrent decline on the cognitive composite
(b 6 SE ¼ 0.47 6 0.06, P ¼ 2  1011). Thirdly, a lower
small-world coefficient at baseline predicted faster neurodegeneration as measured by FDG-PET metabolism (b 6
SE ¼ 0.12 6 0.02, P ¼ 2  108) and precuneus cortical
thinning (b 6 SE ¼ 0.10 6 0.01, P ¼ 4  1012), and
steeper cognitive decline over time (composite b 6 SE ¼
0.08 6 0.02, P ¼ 2  107). Associations for the other
network properties can be found in Supplementary Figs
6–9 in explorative graphs.
We repeated the cross-modal analyses, this time solely
including the mutation carriers who were asymptomatic
at baseline (see Supplementary Table 4). In brief, most
relationships, albeit attenuated, were also present in the
asymptomatic mutation carriers only. The cross-sectional
relationships with the small-world coefficient remained
significant for FDG-PET metabolism and precuneus cortical thickness. All longitudinal relationships indicating
concurrent changes between markers were significant. Of
the third set of models, aimed at predicting the change
over time, two models did not converge (with amyloid
PET and with cognition). The baseline small-world property still predicted the decline of FDG-PET metabolism.

Table 1 Group characteristics

Baseline age, years
Female, N (%)
Estimated years to onset
MMSE
Total MRI scans, 1/2/3/4–6, N
Longitudinal scans, mean (SD)
Follow-up time MRI visits, years
Mutation type, PSEN1/PSEN2/APP, N

Non-carriers (N 5 170)

Asymptomatic mutation carriers (N 5 174)

Symptomatic mutation carriers (N 5 95)

38 (11)
101 (59%)
11 (12)
29.1 (1.2)
84/61/18/7
2.4 (0.8)
3.3 (1.5)
n/a

34 (9)
100 (57%)
14 (8)
29.1 (1.2)
84/59/28/3
2.4 (0.7)
3.2 (1.5)
133/16/25

46 (10)
50 (53%)
1 (7)
22.9 (6.6)
34/30/17/14
2.9 (1.1)
2.2 (1.3)
75/2/18

Mean (SD), unless otherwise specified. EYO is the expected age at onset of the mutation that runs in the family.
MMSE ¼ Mini-Mental State Examination.
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When comparing rates of change over time, mutation
carriers diverged from non-carriers by EYO for all grey
matter network metrics, except connectivity density.
Steeper decline for mutation carriers relative to non-carriers was detected earliest for network size, at baseline
EYO 6.0, followed by small-world coefficient at EYO
4.7, normalized clustering at EYO 4.6, degree at EYO
4.4, normalized path length at EYO 2.8, clustering
coefficient at EYO 2.6 and path length at þ1.0 (Fig. 2,
Supplementary Table 2 and Figs 1 and 2). When additionally adjusting for degree, the estimates for network
metrics yielded similar results, except for clustering coefficient, which lost significance. On a regional level, the earliest steep decline rate for mutation carriers compared to
non-carriers was detected for degree in the lateral occipital gyrus at EYO 7.4, for clustering in the parahippocampal gyrus at EYO 6.2 and for path length in the
precentral gyrus at EYO 4.2. (Fig. 4, Supplementary
Table 3).
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onset. (A, B) P-values based on Kruskal–Wallis, and post hoc Wilcoxin with Holm method correction shown for the comparison of all groups
to the asymptomatic EYO between 15 and 0 mutation carriers group. No covariates included. (C, D) The fitted lines are based on all data
points extending to 38 to þ20. Left of EYO 0 is before expected symptom onset and right of EYO 0 is after expected symptom onset. The
EYO were first jittered, and then the data points before 20 and after EYO þ8 removed to avoid accidental unblinding of participants. Dotted
line is the point of divergence of rate of change between mutation carriers and non-carriers.

Discussion
Using a single-subject approach, we found that structural
grey matter network properties deteriorated over the
course of ADAD and that movement to a more random
network topology closely correlated with cognitive decline. When comparing mutation carriers to non-affected
family members global network disruptions were detected
cross-sectionally as early as 12 years before expected
symptom onset. Longitudinally, increased rates of decline
of network metrics were evident from 6 years before
expected symptom onset. In line with our hypotheses
based on cross-sectional studies in sporadic Alzheimer’s
disease, a lower small worldness of the network was

associated with abnormalities and decline of established
markers of Alzheimer’s disease. Thus, our grey matter
network analysis in this unique cohort of ADAD contributes to our understanding of the Alzheimer’s disease trajectory and indicates that our methods may potentially be
a useful additional non-invasive tool for tracking disease
progression.
As Alzheimer’s disease progresses, there is substantial
amyloid accumulation, volumetric loss, hypometabolism
and cognitive decline, but how grey matter networks fit
into these processes remained unclear. Prior work in
sporadic Alzheimer disease has shown that grey matter
networks might be sensitive to biological changes during
the preclinical stages of the disease (Tijms et al., 2016;
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Figure 2 Small-world coefficient for mutation carriers and non-carriers by group and rate of change by estimated year of
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The fitted lines are based on all data points extending to 38 to þ20. Left of EYO 0 is before expected symptom onset and right of EYO 0 is
after expected symptom onset. The EYO were first jittered and then the data points before 20 and after EYO þ8 removed to avoid accidental
unblinding of participants. Dotted line is the point of divergence between mutation carriers and non-carriers. N ¼ 439.

Ten Kate et al., 2018; Voevodskaya et al., 2018). In the
current work, we observed similar alterations of grey
matter network properties in ADAD as a function of
EYO. The mostly consistent changes in network properties between sporadic and ADAD strengthens the hypothesis that grey matter network disruptions are one of the
downstream effects of amyloid accumulation. Using amyloid PET, we extended previous cross-sectional findings
from studies in sporadic Alzheimer’s disease (Ten Kate

et al., 2018), by showing that higher baseline amyloid
PET and higher amyloid accumulation rates are related
to faster decline of grey matter network properties over
time. Within asymptomatic mutation carriers only, the relationship between amyloid and the small-world coefficient was more subtle and only reached significance when
studying concurrent changes of both markers, possibly
due a decrease in power. The small-world summery
measure was also related to sensitive markers of
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Figure 3 Grey matter network properties by estimated year of onset at baseline between mutation carriers and non-carriers.
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Figure 4 Regional EYO of diversion between mutation
carriers and non-carriers for grey matter network degree,
clustering coefficient and path length. Linear mixed models
adjusted for sex, total grey matter volume and regional volume. MC
¼ mutation carrier; NC ¼ non-carrier. For details, EYO by region
see Supplementary Table 3. N ¼ 416.

carriers in the rate of decline were generally detected later
than cross-sectionally, which could have occurred because
cross-sectional estimates across individuals by EYO may
overestimate changes due to variance in the EYO measure (i.e. some individuals at EYO 12 are actually only
5 or 6 years from actual onset) (McDade et al., 2018).
Another potential cause of cross-sectional and longitudinal estimate differences include sample sizes, with less individuals who had longitudinal data. Measurement
variability over repeated measures within individuals can
also have contributed to later detection of differences in
the longitudinal design if these exceeded subtle rates of
change. Longer follow-up time per individual in larger
visit numbers is necessary for increasingly precise estimates of divergence in change over time.
Altering of network properties was not detected for
every metric. This may be an indication that these metrics
pick up different aspects of neurodegeneration. The
small-world measures (normalized clustering, and normalized path length and small-world coefficient) showed
early cross-sectional changes and seemed most sensitive
to measure change over time. This is in line with network
theory and previous findings in Alzheimer’s disease
(Tijms et al., 2018), which indicated that brain networks
tend to become more similar to random networks over
the disease course. The normalized network metrics reflect how different a network is from random, which
may be why these best capture decline over time. Future
studies are needed to confirm which network property
would be the most robust summary statistic to track longitudinal grey matter network integrity in Alzheimer’s
disease.
On a regional level, cross-sectional network property
alterations were evident earliest in the parietal regions
and then spread across the brain. Most brain regions

Figure 5 Association of amyloid PETwith grey matter network small-world coefficient in mutation carriers. For visualization
purposes, plotted extracted slopes with mixed model and line fitted with simple regression line in ggplot in R. Models to obtain beta and P-values
specified in methods. GM network ¼ grey matter network. Yellow circle ¼ CDR 0 at baseline; Red triangle ¼ CDR >0 at baseline. Amyloid PET
¼ precuneus SUVr, Cross-sectional N¼ 222, Longitudinal N ¼ 120, Predict change N ¼ 131. For other grey matter network metrics see
Supplementary Fig. 6.
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Alzheimer’s disease neurodegeneration and cognitive decline, in cross-sectional and longitudinal design. For these
relationships, the sensitivity analyses in asymptomatic mutation carriers showed that the small-world coefficient already in early disease stages declined concurrently with
other Alzheimer’s disease markers. This suggested these
processes occur, at least partly, in parallel (Wang et al.,
2019), and support the notion that grey matter network
decline is a sign of progression of Alzheimer’s disease.
Previous studies in sporadic Alzheimer’s disease had
suggested decline over time of grey matter network integrity, as there was a decrease over disease stages cross-sectionally (Yao et al., 2010; Tijms et al., 2013b;
Voevodskaya et al., 2018). Here, we show that grey matter networks properties decline over time within individuals, and how decline rates start to increase with disease
severity. Differences between mutation carriers and non-
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cognition. For visualization purposes, plotted extracted slopes with mixed model and line fitted with simple regression line in ggplot in R.
Models to obtain beta and P-values specified in methods. Inversed small-world coefficient to aid visualization, see also Supplementary Table 4.
Yellow circle ¼ CDR 0 at baseline; Red triangle ¼ CDR >0 at baseline. MRI thickness ¼ cortical thickness precuneus; FDG-PET ¼ METAROI
SUVr as described in methods. DIAN composite: equally weighted Z-score of Logical Memory Delayed Recall of the Wechsler memory test,
DIAN Word List Test (comparable to International Shopping List Test), Digit Symbol Substitution Test and Mini-Mental State Examination. Crosssectional FDG-PET N ¼ 238, MR thickness N ¼ 260, Cognition N ¼ 251; Longitudinal: FDG-PET N ¼ 129, MR thickness N ¼ 146, Cognition N
¼ 140; Predict change: FDG-PET N ¼ 131, MR thickness N ¼ 146, Cognition N ¼ 143. For other grey matter network metrics see
Supplementary Figs 7–9.

showed a difference first for path length, then for clustering and then for degree, except for the temporal regions,
in which earlier and more pronounced lowering of the
clustering coefficient was seen. Regional cross-sectional
patterns showed early alterations for path length and
clustering in areas with most pathology in ADAD

including the precuneus. Regions of the default mode network also showed early alterations. Compared to previous sporadic Alzheimer’s disease studies, we find more
widely affected connectivity but the patterns are largely
overlapping (Ten Kate et al., 2018; Tijms et al., 2018;
Verfaillie et al., 2018).
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Figure 6 Associations of grey matter network small-world coefficient with FDG-PET metabolism, cortical thickness and
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properties can reflect the asynchronous start of brain
pathology following Alzheimer’ disease-related cellular
damage and inflammatory processes, informing about
changes in grey matter covariance (Verfaillie et al.,
2018).
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Compared to other structural grey matter imaging, the
cross-sectional differences in the most sensitive grey matter network metrics were detected earlier than cortical
thickness and volumetric measures. It was not part of
this study to investigate whether grey matter network integrity measures have the same or higher sensitivity to
early alterations than other structural MRI markers. Still,
we adjusted for grey matter volume to assure measuring
value beyond simple volumes. The increased rates of
change of network properties were detected at a similar
stage to the volumetrics, and later than precuneus cortical
thinning in dominantly inherited Alzheimer’s disease,
which is the earliest region of change (Gordon et al.,
2018; Kinnunen et al., 2018). The results merit application of grey matter networks in future deeper investigations, for example using multimodal network approaches
with white matter and functional connectivity, to better
understand the substrate of cognitive decline. The observation that network disruptions increase over time in a
large multicentre study is relevant for clinical trials. As
the method only requires standard T1 scans and the
available pipeline for network calculation, a next step is
to test the approach retrospectively in clinical trial
populations.
One of the strengths of the current study design is the
use of a previously validated method for grey matter network extraction. The unique traits of the DIAN cohort
provided the ability to map changes in grey matter networks across decades of disease time. It should be noted
that the estimates as a function of the expected symptom
onset in dominantly inherited Alzheimer’s disease are
influenced by sample size. Still, this method provides a
way to detect and compare changes due to Alzheimer’s
disease before symptom onset, and combine different
families. Additionally, the rich characterization of DIAN
participants provided the ability to relate observed
changes in networks to other neuroimaging markers of
pathology as well as cognition. A potential limitation is
that our study included an average time period of 3 years
in the longitudinal cohort, which may not be enough
time to reliably measure changes due to Alzheimer’s disease in its very early stages. Yet, we show the longitudinal analysis of structural grey matter networks alongside
of the cross-sectional results, which to the best of our
knowledge has not been studied before and warrants further investigation of how grey matter network integrity
decreases over time in sporadic Alzheimer’s disease.
In conclusion, in ADAD individual grey matter network
properties are robustly associated with Alzheimer’s disease severity and progression as shown by the associations with EYO, amyloid accumulation, rate of
neurodegeneration and cognitive decline. These data suggest that single-subject grey matter network integrity
measures obtained from structural MRI scans provide an
additional, non-invasive tool for understanding and measuring progression from preclinical to severe clinical stages
of Alzheimer’s disease. These grey matter network
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